Medcura, Inc.

Meet Kenneth Renkens, M.D., our esteemed Chief Medical Officer, internationally renowned neurosurgeon, and co-founder of the Indiana Spine Group. With 30 years of experience in the implantable surgical innovation space and involvement in 5 investigational hemostasis spine studies, Dr. Renkens has joined the Medcura team to lead clinical innovation of surgical hemostatic agents. “LifeGel is a particularly meaningful advancement in spine surgery where swelling of current flowable hemostatic agents in confined spaces has been known to cause neurological deficits, including paralysis,” says Dr. Renkens. With invaluable insights from Dr. Renkens, our team is thrilled for the future pioneering that our advanced technology has the potential to bring to spinal procedures. Medcura was recently awarded FDA’s Breakthrough Device Designation for the “no- swell” properties of its LifeGel hemostatic gel. Once approved, LifeGel will be the only absorbable hemostatic agent indicated for use in confined areas and will have the following labeling: “Due to its no-swell properties, LifeGel can be used in surgical procedures where swelling cannot be tolerated.” To learn more about LifeGel, visit www.Medcurainc.com. #orthopedics #spinesurgery #orthopedicsurgery

LifeGel™ is the first and only absorbable hemostatic agent to receive an FDA breakthrough designation for surgical procedures where swelling cannot be tolerated, an advantage that could be especially critical when used in confined anatomical spaces where these products are often used. The LifeGel™ technology achieves hemostasis by mechanical means, coating the bleeding site via the process of mucoadhesion. To learn more, go to www.medcurainc.com. #biotech #surgery #breakthrough

Medcura, Inc. has closed a private placement with aggregate gross proceeds of $22.4 million. We will use these funds to accelerate the development of our lead surgical product, LifeGel™ Absorbable Hemostatic Gel, complete pre-clinical testing of the product, and file an Investigational Device Exemption for LifeGel with the U.S. FDA to support an investigational study focused on stopping bleeding in spinal surgery. Current hemostatic agents swell and can cause neurological issues, including paralysis, when used in confined spaces routinely addressed in spinal surgery.   Medcura’s Chief Executive Officer Jim Buck stated, “We remain highly encouraged by the continued momentum and pace of successes around our Life™ platform of innovative surgical hemostatic agents. Our new and existing investor partners understand, and are aligned with, the Company’s strategy to seismically transform the $2.8 billion worldwide biosurgery market for hemostatic agents. This funding support is timely and crucial to further advance our progress into a pivotal clinical trial and global commercialization of the platform’s lead product, LifeGel.”  #biotech #surgery #Medcura

At Medcura, our FDA designated breakthrough biopolymer technologies and LifeGel™ platform are redefining hemostasis with solutions designed to address real problems — for patients, surgeons, and payers. To learn more or see it in action, visit Medcura’s new website at www.medcurainc.com.

Learn how surgical hemostasis technology has evolved and what it means for healthcare and your practice, with Dr. Matthew Dowling, pioneer, and Chief Scientific Officer. Discover how LifeGel™ Absorbable Hemostasis Gel is being developed to elevate the quality, convenience, and cost equation for bleeding control— with a single solution for routine to complex procedures. For more information about the FDA Breakthrough Device Indication or to download the video, go to: www.medcurainc.com #Medcura #LifeGel #surgicalinnovation #hemostasis #bleeding

Learn about the successful launch of RapidSeal™ and how the Life™ technology portfolio is elevating the standard for bleeding control — from consumer to surgical applications–with a convenient, absorbable gel. To RSVP or for more information go to: https://lnkd.in/e_-Xy9FS #bioengineering #healthcareinnovation #Medcura #RapidSeal #lecture #universityofmaryland

We're thrilled to introduce a dynamic duo joining our Medcura family: Dr. John Barry and John McAfee, Esq. Dr. Barry, Group Vice President of R&D and Operations, brings over two decades of experience spearheading cutting-edge medical device and biosurgery projects at Miromatrix Medical and Baxter Advanced Surgery. With his visionary leadership, we're well positioned to rapidly advance our surgical bleeding control platforms and expand our other consumer, vascular closure and military product lines. "Medcura gives me a rare opportunity to develop and commercialize truly life-changing products and that’s exciting," said Dr. Barry. We couldn't agree more. 🌍 J.P. McAfee, Esq, our Vice President of Legal and Compliance, brings eight years of experience in the medical device industry. He's joining us most recently from biosurgery innovator Biom'up USA, Inc. and before that, spinal leader Globus Medical Inc.. J.P.'s role as general counsel will greatly assist us as we navigate the highly regulated industry waters successfully. These additions bolster our mission to advance the LifeGel™ Absorbable Hemostatic Gel and the Medcura Life™ platform. Together, we're setting our sights on capturing standard of care use in multiple large segments of the +$2.5 billion market for these vital bleeding control technologies. 💡 Join us in welcoming Dr. John Barry and J.P. McAfee to the Medcura team! Their expertise and passion for innovation align perfectly with our commitment to bringing groundbreaking products to the patients around the world that need them. 🚀 #Medcura #Innovation #Medtech #WelcomeToTheTeam

CSO, Dr. Matthew Dowling will discuss the breakthrough technology LifeFoam, which has shown a significant advance in survival outcomes in vivo in a model of lethal non-compressible hemorrhage. Non-compressible hemorrhage accounts for 85% of all hemorrhage related deaths and is the leading cause of preventable fatality on the battlefield. #biotech #sciencenews #militaryhealth #militarytechnology #conferencespeaker